Spotlight on CDD Research

Alzheimer’s Disease Research

Profs Robert Vince and Swati More have developed a noninvasive imaging technique that tracks accumulation of the Alzheimer’s peptide, amyloid-β, in the eye.

ProteXidine^TM: Anti-Aging & Skin Care

CDD has developed a patented technology that prevents undesirable skin damage by both boosting the proportion of key DNA repair enzymes in the skin and filtering out damaging UV rays.

Pre-Clinical Study for Cyanide Antidote

A faster acting and safer than existing options, an antidote for cyanide poisoning that works prophylactically to prevent or limit toxicity associated from exposure to cyanide has been developed.

Areas of Research

The research conducted at the Center for Drug Design (CDD) includes the design, discovery and development of therapeutics for various conditions affecting human health. Current active research areas include neurological and viral diseases. Along with a proven track record of success in developing compounds of medicinal interest (carbovir and abacavir), the CDD continuously adds preclinical drug candidates to its growing repertoire. The CDD has partnered with Topix Pharmaceuticals to launch a line of ProteXidine® products to boost skin health. The CDD has also rolled out, in combination with the imaging company Retispec, a hyperspectral eye scanner to identify and diagnose patients who have, or are at risk for, Alzheimer’s disease.

Expand all